Fundz
Real-time · AI · Cross-signal

Discover the power of real-time signals plus AI

Every contract, funding round, exec hire, and M&A move on FibroBiologics — with verified, ICP-scored contact reveals (email + mobile) on demand.

Trusted by founders, sales teams, recruiters, and investors at firms like BlackRock, Oracle, Kleiner Perkins, and HubSpot.

See plansBook a 15-min walkthrough
Watch the 2-minute tour · with sound

FibroBiologics Engages Southern Star Research as CRO in Australia

Sep 19, 2024over 1 year ago

Contract Type

partnership

HoustonBiotechnologyHealth CareTherapeutics

Description

FibroBiologics has engaged with Southern Star Research to provide clinical research organization (CRO) services in Australia, including preparatory work for a Phase 1/2 clinical trial utilizing product candidate, CYWC628, to treat diabetic foot ulcers. This partnership marks an important step forward in creating the infrastructure for FibroBiologics to conduct clinical trials in Australia.

Company Information

Company

FibroBiologics

Location

455 E. Medical Center Blvd, Suite 300

Houston, Texas, United States

About

FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 275+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration.

Predictive Intelligence
Strategic

ML-powered predictions for FibroBiologics's next move

Learn about Strategic plan

Related People

Suggested for you

Sign in to view contact details

Agreement Insights

Based on industry data
Strategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months